Autopsy report · NCT01120431

Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)

“Strategic business decision (not related to safety or efficacy concerns)”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Baxter Healthcare Corporation

Sponsor type

Industry

Conditions

Dehydration

Interventions

Oral rehydration fluid; Isotonic hydration fluid and recombinant human hyaluronidase

Participants

0

Trials that died the same way

• A Study of RBI-4000 in Healthy Participants
  “Strategic business decision (not related to safety, efficacy, or quality)” (97% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (91% match in meaning)
• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (86% match in meaning)
• The KHENERGYC Study
  “Strategic company decision - not related to safety concerns” (85% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.